Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
SAN FRANCISCO, May 07, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in Solid Biosciences, Inc. (NASDAQ:SLDB) of the May 29, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased Solid Biosciences securities pursuant and/or traceable to its January 25, 2018 initial public offering and/or on the open market between January 25, 2018 and March 14, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/SLDB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
Defendants conducted an initial public offering of Solid Biosciences on or about January 25, 2018. In this IPO, the Company sold approximately 7 million shares at $16 per share to investors.
On March 15, 2018, Defendants announced the U.S. Food and Drug Administration placed a clinical hold on the Company’s Phase 1/2 trial assessing its SGT-001 drug in patients with Duchenne muscular dystrophy. This news drove the price of Solid Biosciences shares down $16.99, or about 65%, to close at $9.32.
The Motley Fool later reported that just prior to the IPO, a prominent researcher left its board because of risks associated with the drug delivery method for Solid Biosciences’ SGT-001 drug.
“We’re focused on investors’ losses and Defendants’ disclosures about internal concerns over the safety of the SGT-001 delivery method leading up to- and after- the IPO,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Solid Biosciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
